TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35432163
Drug: Prism Adaptation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prism Adaptation Treatment (PAT)
Study: 35432163
Drug: Alternative therapies
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative therapies (Control)
Study: 35432352
Drug: Anti-CD30 CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CD30 CAR-T therapy combined with PD-1 inhibitor
Study: 35432352
Drug: Lymphocyte-depleting chemotherapy
Normalized name: Therapeutic allogeneic lymphocytes
DrugBank: Therapeutic allogeneic lymphocytes (DB17459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphocyte-depleting chemotherapy with fludarabine and cyclophosphamide
Study: 35433774
Drug: Probiotic intake
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic intake (from yoghurts or dietary supplements)
Study: 35434343
Drug: Pembrolizumab given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab given 2-3 weeks prior to chemoradiation and then, q21 days concurrently with high-dose cisplatin and radiation prescribed to a total dose of 70 Gy.
Study: 35434725
Drug: Allopurinol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (100 mg daily, titrated to 800 mg)
Study: 35434725
Drug: Febuxostat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (40 mg daily, titrated to 120 mg)
Study: 35434725
Drug: Allopurinol and
Normalized name: Allopurinol and lesinurad only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol and Febuxostat (both treatments)
Study: 35435222
Drug: Virus-specific antibodies
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virus-specific antibodies (IgM/IgG) and T-cell responses (CD4+/CD8+)
Study: 35435222
Drug: Virus-specific antibodies
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virus-specific antibodies (IgM/IgG) only
Study: 35435222
Drug: Virus-specific antibodies
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virus-specific antibodies
Study: 35435625
Drug: Tarloxotinib 150
Normalized name: Tarloxotinib
DrugBank: Tarloxotinib (DB14944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tarloxotinib 150 mg/m2 on days 1, 8, 15, and 22 in a 28-day cycle
Study: 35435984
Drug: Autologous CD7-CAR
Normalized name: Autologous bi-epitope BCMA-targeted CAR T-cells
DrugBank: Ciltacabtagene autoleucel (DB16738)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous CD7-CAR T-cell infusion
Study: 35436365
Drug: Transdermal 17β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β oestradiol (17βE) starting dose of 12.5 mcg increasing to 25 mcg after 4 months, patch changed twice weekly for a total of 8 months
Study: 35436365
Drug: Transdermal 17β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β oestradiol (17βE)
Study: 35437075
Drug: POMAQ and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: POMAQ and ancillary sources (e.g. electronic medical records, urine toxicity screen)
Study: 35438082
Drug: Aerobic interval
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic interval training intervention (3-weekly, 4-month duration)
Study: 35438144
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals treatment for hepatitis C
Study: 35438338
Drug: Web-based oncofertility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based oncofertility support tool (Preparation for Decision-Making Scale for patients)
Study: 35438338
Drug: Web-based oncofertility
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based oncofertility support tool (Preparation for Decision-Making Scale for healthcare providers)
Study: 35439028
Drug: Narsoplimab (OMS721),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narsoplimab (OMS721), intravenous once weekly for 4-8 weeks
Study: 35439166
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell receptor (TCR) immunosequencing assay
Study: 35439298
Drug: Recombinant von
Normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant von Willebrand factor (rVWF; vonicog alfa) prophylaxis, starting dose 50 ± 10 VWF:RCo IU/kg twice weekly for 12 months (prior on-demand group)
Study: 35439298
Drug: Recombinant von
Normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant von Willebrand factor (rVWF; vonicog alfa) prophylaxis based on prior plasma-derived VWF (pdVWF) weekly dose/dosing frequency for 12 months (switch group)
Study: 35439353
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg administered orally
Study: 35440569
Drug: Pharmacologic interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacologic interventions targeting AKT mutations, specific details on dosage and duration not available
Study: 35441164
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine (two doses, 0-14 days apart)
Study: 35441935
Drug: Nonsteroidal mineralocorticoid
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal mineralocorticoid receptor antagonists (NS-MRAs), specifically finerenone
Study: 35442137
Drug: single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: single agent PF-04518600 (OX40 agonist monoclonal antibody)
Study: 35442137
Drug: azacitidine +
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: azacitidine + avelumab (anti-PD-L1 monoclonal antibody) + GO
Study: 35442228
Drug: Control (baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (baseline measurement before treatment)
Study: 35442228
Drug: Acid-blocking medications
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acid-blocking medications
Study: 35442238
Drug: Sebelipase alfa
Normalized name: Sebelipase alfa
DrugBank: Sebelipase alfa (DB11563)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sebelipase alfa 1.0 mg/kg by intravenous infusion every other week for up to 144 weeks (with dose escalation to 3.0 mg/kg qow and subsequently to 3.0 mg/kg weekly permitted)
Study: 35442962
Drug: Omeprazole and
Normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole and amoxicillin/clarithromycin
Study: 35442962
Drug: Omeprazole and
Normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole and amoxicillin/levofloxacin
Study: 35443252
Drug: PIM1 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PIM1 inhibitor SGI-1776
Study: 35443252
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of SGI-1776
Study: 35443783
Drug: Facilitated subcutaneous
Normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facilitated subcutaneous immunoglobulin treatment
Study: 35443947
Drug: Blonanserin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blonanserin (4 mg P.O. twice per day, increased to 8-16 mg/d for 26 weeks, max 24 mg/day)
Study: 35443984
Drug: Initial antihypertensive
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antihypertensive class
Study: 35444059
Drug: BEMPEG (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEMPEG (0.8 mg/kg; intravenously) + NKTR-262 (0.5 mg/kg; intratumoral)
Study: 35444471
Drug: Increased intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased intake of fish and fresh fruits, drinking water, and use of oral contraceptive pills
Study: 35444567
Drug: Expectation-optimised video
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation-optimised video with patients giving additional information about their mostly positive therapy outcomes
Study: 35445027
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of Non-HLA-Matched Off-the-Shelf
Study: 35446934
Drug: CD19-CAR T-cell
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19-CAR T-cell therapy
Study: 35446944
Drug: Favipiravir (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Favipiravir (1800 mg BID day 1, 800 mg BID days 2-10)
Study: 35447145
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% imiquimod cream, applied 3 times a week for 16 weeks
Study: 35448002
Drug: Anlotinib (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib (12 mg daily during HSRT, adjuvant d1-14 every 3 weeks)
Study: 35449189
Drug: Iontophorised Acetylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iontophorised Acetylcholine (ACh) at 5 concentrations (0.0001% to 1%) administered via three consecutive pulses of 0.02 mA for 10 min each
Study: 35449247
Drug: Carbohydrate ingestion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate ingestion group (400 mL of carbohydrate-containing fluid two hours prior to surgery)
Study: 35449533
Drug: Guideline directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline directed oral anticoagulants (OACs) including direct oral anticoagulants (DOACs)
Study: 35450679
Drug: Unplanned DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unplanned DAPT discontinuation
Study: 35450679
Drug: Unplanned DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unplanned DAPT discontinuation ≥3 weeks after PCI
Study: 35450679
Drug: Planned DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned DAPT discontinuation
Study: 35450750
Drug: On-treatment low-density
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-treatment low-density lipoprotein cholesterol (LDL-C)
Study: 35450817
Drug: Low-intensity chemotherapy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity chemotherapy
Study: 35451010
Drug: Endoluminal vacuum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoluminal vacuum therapy (EVT) using Eso-Sponge®
Study: 35451176
Drug: Voxelotor treatment
Normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Voxelotor treatment for up to 48 weeks
Study: 35452178
Drug: Newer disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer disease-modifying therapies being developed and studied
Study: 35452519
Drug: Leronlimab (CCR5-binding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leronlimab (CCR5-binding antibody), specific dosage and duration not mentioned
Study: 35453064
Drug: Perampanel (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (median maximum dose 6.0 mg/day)
Study: 35454839
Drug: Noninvasive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive physical plasma (NIPP) treatment
Study: 35454839
Drug: NIPP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIPP treatment
Study: 35455660
Drug: Intravenous antiarrhythmic
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antiarrhythmic agents (amiodarone, vernakalant, ibutilide)
Study: 35456277
Drug: Neurological music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurological music therapy for 3 months
Study: 35460043
Drug: Lixisenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (10 μg sc)
Study: 35460313
Drug: Pain management
Normalized name: Olu Pain Management 4%-1% Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain management at haemophilia treatment centres (HTC)
Study: 35460313
Drug: Management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Management of depression/anxiety at haemophilia treatment centres (HTC)
Study: 35460412
Drug: Ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian stimulation during IUI treatment
Study: 35460497
Drug: Repository corticotropin
Normalized name: Repository Corticotropin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repository corticotropin injection (RCI; Acthar® Gel); 80 U subcutaneously twice weekly for 12 weeks
Study: 35460976
Drug: Gamma-secretase inhibitor
Normalized name: gamma-octalactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gamma-secretase inhibitor AL102
Study: 35460976
Drug: Beta-catenin inhibitor
Normalized name: cefpodoxime and beta-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-catenin inhibitor Tegavivint (BC2059)
Study: 35461262
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) scopolamine administered over the course of 2 weeks with three blinded infusions.
Study: 35461262
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered over the course of 2 weeks with three blinded infusions.
Study: 35463939
Drug: Effective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective treatment (including rescue FMT)
Study: 35465706
Drug: Artemisinin-naphthoquine (ART-NQ)
Normalized name: naphthoquine
DrugBank: Naphthoquine (DB16249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-naphthoquine (ART-NQ) single doses of 20 mg/kg for artemisinin and 8 mg/kg for naphthoquine.
Study: 35466039
Drug: One antipseudomonal
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One antipseudomonal class (e.g., beta-lactam)
Study: 35466039
Drug: Two antipseudomonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two antipseudomonal classes (e.g., beta-lactam/aminoglycoside)
Study: 35466039
Drug: Three or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three or more antipseudomonal classes (e.g., beta-lactam/aminoglycoside/fluoroquinolone)
Study: 35466524
Drug: ADI-PEG20 (pegargiminase)
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADI-PEG20 (pegargiminase) combined with pemetrexed (500 mg/m²) and cisplatin (dosage not specified)
Study: 35467243
Drug: Eftozanermin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eftozanermin alfa (eftoza) 2.5-15 mg/kg intravenously on day 1 or day 1/day 8 every 21 days (dose-escalation phase)
Study: 35467243
Drug: Eftozanermin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eftozanermin alfa (eftoza) 1.25-7.5 mg/kg once-weekly (QW) (dose-optimization phase)
Study: 35467749
Drug: Selumetinib at
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib at 25 mg/m2 orally twice daily
Study: 35468336
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of BNT162b2 vaccine
Study: 35468336
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of BNT162b2 vaccine
Study: 35468690
Drug: Cultured autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultured autologous bone marrow MSCs matrix (CC group)
Study: 35469288
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab
Study: 35469288
Drug: Combined intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intravitreal injection of 0.05 mL (0.5 mg) of ranibizumab and suprachoroidal injection of triamcinolone acetonide (4mg/0.1mL)
Study: 35469443
Drug: Intravenous fosphenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosphenytoin plus oral tapering of phenytoin
Study: 35469846
Drug: VAS2870 (NADPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAS2870 (NADPH oxidase inhibitor)
Study: 35469846
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antioxidant treatment)
Study: 35470225
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate 30 mg plus meloxicam 30 mg
Study: 35470855
Drug: High consumption
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High consumption of ultra-processed foods (721 ± 341 g/d, 28% of total food intake)
Study: 35471240
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily activities without modification)
Study: 35472295
Drug: New Covid-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Covid-19 vaccines
Study: 35472295
Drug: Active controls
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active controls (existing vaccines)
Study: 35473396
Drug: Thyroid-Stimulating Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid-Stimulating Hormone and Thyroid Hormones
Study: 35473676
Drug: Beta-blockers (prescribed)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (prescribed)
Study: 35473676
Drug: Beta-blockers (unprescribed)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (unprescribed)
Study: 35473709
Drug: Il-6 inhibitors
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Il-6 inhibitors and monoclonal antibodies
Study: 35473709
Drug: Specific antiviral
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific antiviral therapies
Study: 35473726
Drug: CL2020 cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: CL2020 cells (1.5 million cells for low-dose cohort, 15 million cells for high-dose cohort)
Study: 35475157
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg/day) + ADT
Study: 35475157
Drug: Flutamide (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (375 mg/day) + ADT
Study: 35475300
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (DPNB with ropivacaine + tetracaine gel)
Study: 35475300
Drug: Tetracaine gel
Normalized name: Tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracaine gel group (DPNB with saline)
Study: 35475789
Drug: Active transcranial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active transcranial alternating current stimulation with cognitive treatment
Study: 35475885
Drug: Treg DLI
Normalized name: DLin-MC3-DMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treg DLI plus low-dose interleukin-2 (LD IL-2)
Study: 35475910
Drug: IL-15 (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-15 (0.5, 1, and 2 μg/kg subcutaneously 5 days per week for 2 weeks)
Study: 35475982
Drug: Simulation-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulation-based training (40-minute immersive individual simulation training focusing on high-risk medications in older adults)
Study: 35476127
Drug: WT1 recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: WT1 recombinant protein vaccination (WT1-A10) with vaccine adjuvant AS01
Study: 35476252
Drug: Antiestrogen hormonal
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiestrogen hormonal therapy
Study: 35476550
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy for ER+/Basal tumors (15% of ER+, HER2- tumors reclassified by 80-GS)
Study: 35476550
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy for ER+/Luminal subtype
Study: 35477175
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of Hydroxyurea (HU) and thalidomide for 6 months
Study: 35477380
Drug: HIP-REP intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIP-REP intervention based on Activity of Daily Living
Study: 35477725
Drug: MAD0004J08 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAD0004J08 (single dose via intramuscular injection)
Study: 35478081
Drug: Composite comparator
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite comparator (LAMA/LABA therapies)
Study: 35478711
Drug: CCCG-LBL-2016 regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCCG-LBL-2016 regimen combined with dasatinib and prophylactic intrathecal infusion
Study: 35478711
Drug: BCR-ABL tyrosine
Normalized name: BCR-ABL tyrosine kinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCR-ABL tyrosine kinase inhibitor (TKI) dasatinib
Study: 35482408
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy with highly neutralizing plasma
Study: 35482408
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma therapy with high neutralizing antibodies
Study: 35482538
Drug: Blinatumomab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (15 μg/m)